Page 21 - Pharma Sector

Torrent Pharma tanks 4% post Q1FY25 results; analysts update target prices

Shares of Torrent Pharma slumped up to 4.26 per cent at Rs 646.70 per share on the BSE in Tuesday's intraday deals. This came despite the Indian drugmaker delivering a strong April-June quarter

IOL Chemicals zooms 5% on drug nod from European regulator: details here

OL Chemicals and Pharmaceuticals stock surged up to 4.59 per cent at Rs 415.15 per share on the BSE in Wednesday's intraday trade

Cipla Q1 Preview: Restructure in biz may dent sales; profits to rise 7%

Cipla is expected to see a decent June quarter with revenues estimated to increase in upper single digits on a year on year basis and net profits seeing a mid single digit growth

US Biosecure Act spells long-term boost for Indian CDMO, CRO firms

As American biopharma looks to diversify sourcing, Indian companies stand to benefit

Zydus Life Vadodara facility gets OAI report from USFDA, stock falls 3%

The fall in the stock came after the company announced that it has secured an Official Action Indicated (OAI) report from the United States Food and Drug Administration (USFDA).

Aurobindo Pharma board approves share buyback plan worth Rs 750 cr

Aurobindo Pharma on Thursday said its board has approved a share buyback plan of up to Rs 750 crore. The company's board has approved the buyback of up to 51,36,986 shares representing up to 0.88 per cent of the total paid-up equity share capital, Aurobindo Pharma said in a regulatory filing. The company will buy the shares at Rs 1,460 apiece for an aggregate amount of up to Rs 750 crore, it added. The drug firm said July 30 has been fixed as the record date for the Rs 750-crore share buyback scheme through the tender offer route. At the end of June 30, the company promoters owned 51.8 per cent stake, while foreign institutional investors (FIIs) and mutual funds owned 16.73 per cent and 19.17 per cent respectively. Shares of Aurobindo Pharma were trading 2.83 per cent down at Rs 1,332.90 apiece on the BSE.

Zensar acquires BridgeView to expand into biopharma, life sciences industry

The acquisition is expected to be completed tentatively within 2-3 weeks

Pharma and healthcare sector seals $4.1 bn deals in Q2 2024: Report

The average deal size also saw a jump, rising from $9.7 million in Q1 calendar year 2024 to $74 million in Q2 2024

Lupin divests women's health specialty biz in US to Evofem Biosciences

Company says divestment aligns US specialty business with therapeutic areas like respiratory, neurology

Mankind Pharma rallies 5% after 3.7 mn shares change hands via block deal

Mankind Pharma, the domestic pharmaceutical major's stock price surged up to 5.27 per cent at Rs 2,215 per share on the BSE in Wednesday's intraday trade

Centre fails to form policy on online sale of drugs ahead of HC deadline

The Delhi HC had in March this year, given the government a final opportunity to frame a policy within four months, failing which, the court had stated it would hear the matter on merits

Indian pharmaceutical market registers over 8% growth in June 2024

GSK's antibiotic drug Augmentin and USV's anti-diabetic drug Glycomet GP continued to be the top-selling medicine brands with sales of Rs 76 crore and Rs 66 crore, respectively

Indian pharma firms seek govt tax reliefs, incentives to spur innovation

The upcoming budget would be Modi's first major policy announcement in his third term as prime minister

This pharma stock has surged 16% on Friday; zoomed over 100% so far in CY24

Shilpa Medicare hit a multi-year high of Rs 672.50, rallied 16% after the company's CDMO customer reported positive results from pivotal clinical trial & placed binding purchase order.

Healthcare at new high; Lupin, Glenmark among 5 stocks for up to 15% upside

5 breakout pharma stocks: Glenmark, Lupin, Laurus Labs, Dr Lal PathLabs and Zydus Life can potentially rally up to 15 per cent, suggest charts.

Mumbai-based Wockhardt to launch its novel antibiotic Zaynich by FY25-end

Global launch in FY26 after multinational clinical trial ends

Orchid Pharma join hands with Cipla to launch new antibiotic in India

The partnership between Orchid Pharma and Cipla combines Orchid's innovative drug development capabilities with Cipla's extensive distribution network and market presence

India to make Ozempic-like drugs for diabetes, obesity under PLI by 2026

GLP-1RA works by activating GLP-1 receptors in the pancreas, which leads to enhanced insulin release and reduced glucagon release responses

Online pharmacy players look for regulatory framework for industry

A division bench of the Madras HC has set aside an earlier order that disallowed them to engage in digital sale of medicines

'$10 bn opportunity up for grabs in off patent drug market by 2029'

As many as 15 blockbuster drugs whose revenues worth USD 112 billion will be off-patented during 2023 to 2029 and the Indian pharma industry will have a growth opportunity of USD 10 billion in the form of generics (including complex), a top official of Pharmaceuticals Export Promotion Council of India (Pharmexcil), a body under the Department of Commerce said on Thursday. Addressing a press conference, Udaya Bhaskar, Director General of Pharmexcil also said Indian pharma exports recorded 8.85 per cent growth during April and May this year at USD 4.73 billion against USD 4.35 billion during the same period last fiscal. He further said with the advent of quality concerns raised by global regulatory agencies, Pharmexcil's priority has been shifted to quality management and imbibing quality culture in the industry by way of organising capacity building programmes in states to uphold the image of Indian pharma on global platform. According to the pharma exports body, India has 748 US Foo